Natera

Warning: The NIPT Growth Story May be Ending

A good disruptive technology can succeed in creating a market that didn’t exist before by meeting a need that people didn’t know they needed. Take non-invasive prenatal testing (NIPT) which is defined as “testing for diseases or conditions in a fetus or embryo before it is born“. The idea is to find out if your newly […]

A Prenatal Testing IPO from Ariosa Diagnostics

In a previous article, we highlighted Natera, a non-invasive prenatal testing (NIPT) company that has strong financial backing and a test that is said to consistently demonstrate high sensitivity and specificity for all major aneuploidies beyond Down syndrome. Although Sequenom (NASDAQ:SQNM) is the market leader in NIPT with more than 60% market share, there is plenty of growth to go […]

Prenatal Testing by Natera

Non-invasive Prenatal Testing (NIPT) is a blood test used to screen pregnant women for chromosome problems, as early as 9 weeks in pregnancy. MaterniT21 was the first NIPT made available in 2011 by Sequenom (NASDAQ:SQNM) and since then has been the market leader with more than 60% market share according to the company. In a report published this […]